Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL

Trial Profile

Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Dinaciclib (Primary) ; Ofatumumab (Primary)
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 4 Mar 2015.
    • 23 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top